Fluent BioSciences
Develops high sensitivity molecular analytical products that enables usage of extremely low molecular and cellular sample inputs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Fluent BioSciences, founded in 2018, specializes in single-cell RNA sequencing (scRNA-seq) technologies designed to advance scientific research. The company operates in the life sciences market, providing RNA sequencing kits and platforms that enable researchers to analyze individual cells with high precision. Fluent BioSciences serves academic institutions, biotechnology firms, and pharmaceutical companies, offering products like the PIPseq platform and SEA Kit for custom applications. The business model revolves around selling these specialized kits and platforms, generating revenue through direct sales and long-term partnerships. The company's technology allows for rapid processing of fresh samples, ensuring high-quality data without sample degradation. Fluent BioSciences is backed by leading early-stage life science investors and guided by a team of industry veterans with extensive experience in commercializing life science technologies.
Keywords: single-cell RNA sequencing, scRNA-seq, PIPseq platform, SEA Kit, life sciences, biotechnology, pharmaceutical research, high-quality data, rapid processing, custom applications.